80 Participants NeededMy employer runs this trial

Deep Brain Stimulation for Speech Sequencing in Parkinson's Disease

Recruiting at 1 trial location
FH
BG
Overseen ByBarbara G Holland, MA
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Boston University Charles River Campus
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study will examine how two important brain circuits - one involving the subthalamic nucleus (STN) and one involving the ventral intermediate nucleus of the thalamus (VIM) - contribute to learning and producing speech sequences. Participants will include two groups: 1. individuals with Parkinson's disease who have deep brain stimulation (DBS) devices targeting the STN and 2. individuals with essential tremor who have DBS devices targeting the VIM.

Participants will complete speech tasks involving the learning and repetition of novel sound sequences. During some parts of the study, DBS stimulation will be temporarily turned on or off in a controlled research setting. This will allow researchers to examine how stimulation affects both the learning of new speech sequences and the production of previously learned sequences. All STN participants and most VIM participants will also be equipped with a cutting-edge DBS system, the Percept PC, which will enable the recording of deep brain activity during the tasks.

The results of this study will improve our understanding of how different brain circuits support speech learning and production. In particular, this study will help to differentiate the roles of the STN and VIM in learning the ordering of speech sounds within a syllable from learning of speech sequences containing multiple syllables. This knowledge may help guide future approaches to optimizing DBS settings to improve both movement and speech outcomes in individuals with neurological disorders, as well as provide greater general insight into how these brain structures contribute to speech production and learning.

Who Is on the Research Team?

FH

Frank H Guenther, Ph.D.

Principal Investigator

Boston University

Are You a Good Fit for This Trial?

Inclusion Criteria

Corrected vision adequate to easily read text presented during speech motor task
Stable DBS program settings for at least one month
I am a native speaker of American English.
See 7 more

Exclusion Criteria

Pregnancy
For participants in the sub-syllabic sequence learning study (Study C.2.1), experience with the following languages: Hebrew, Polish, Lithuanian, Romanian, Georgian, Tepehua, Hungarian, and Pima
I do not have significant memory or thinking problems or active severe mental health symptoms.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Baseline Assessment

Participants undergo cognitive and motor assessments to establish baseline measures

1 day
1 visit (in-person)

Treatment

Participants complete speech tasks with DBS stimulation turned on and off to study effects on speech sequencing

1 day
1 visit (in-person)

Follow-up

Participants are monitored for any changes in speech production and cognitive function post-treatment

2-4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Cessation and re-enabling of stimulation of the STN
  • Cessation and re-enabling of stimulation of the VIM thalamic nucleus
  • Multisyllabic sequence learning
  • Phoneme sequence learning

How Is the Trial Designed?

4

Treatment groups

Experimental Treatment

Group I: Ventral intermediate thalamus with subsyllabic learning armExperimental Treatment2 Interventions
Group II: Ventral intermediate thalamus with multisyllabic learning armExperimental Treatment2 Interventions
Group III: Subthalamic nucleus with subsyllabic learning armExperimental Treatment2 Interventions
Group IV: Subthalamic nucleus with multisyllabic learning armExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Boston University Charles River Campus

Lead Sponsor

Trials
125
Recruited
14,100+

Massachusetts General Hospital

Collaborator

Trials
3,066
Recruited
13,430,000+

National Institute on Deafness and Other Communication Disorders (NIDCD)

Collaborator

Trials
377
Recruited
190,000+